Kanakinumab (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Kanakinumab" in Polish language version.

refsWebsite

Global rank Polish rank

2^nd place

6^th place

4^th place

7^th place

2web.archive.org

1^st place

1^st place

2clinicaltrials.gov

5,225^th place

3,508^th place

low place

low place

1landesbioscience.com

low place

low place

low place

low place

68^th place

31^st place

clinicaltrials.gov

Safety, Tolerability and Efficacy of ACZ885 (Canakinumab) in Patients With Active Rheumatoid Arthritis, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT00784628 [dostęp 2010-08-21] (ang.).
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01327846 [dostęp 2017-11-18] (ang.).

doi.org

Eugen Dhimolea. Canakinumab. „MAbs”. 2 (1), s. 3–13, 2010. DOI: 10.4161/mabs.2.1.10328. PMID: 20065636. PMCID: PMC2828573.
HJ Lachmann, Kone-Paut I, Kuemmerle-Deschner JB i wsp. Use of canakinumab in the cryopyrin-associated periodic syndrome. „New Engl J Med”. 360 (23), s. 2416–2425, 4 czerwca 2009. DOI: 10.1056/NEJMoa0810787. PMID: 19494217.
Yasothan U, Kar S. Therapies for COPD. „Nat Rev Drug Discov”. 7 (4), s. 285, 2008. DOI: 10.1038/nrd2533.

europa.eu

ema.europa.eu

Streszczenie EPAR dla ogółu społeczeństwa – Ilaris (kanakinumab). EMA. [dostęp 2014-06-14]. (pol.).

landesbioscience.com

Eugen Dhimolea. Canakinumab. „MAbs”. 2 (1), s. 3–13, 2010. DOI: 10.4161/mabs.2.1.10328. PMID: 20065636. PMCID: PMC2828573.

nelm.nhs.uk

Yuet Wan: Canakinumab (Ilaris) and rilonacept (Arcalyst) approved in EU for treatment of cryopyrin-associated periodic syndrome. National electronic Library for Medicines, 2009-10-29. [dostęp 2010-04-14]. [zarchiwizowane z tego adresu (2012-02-26)].

nih.gov

ncbi.nlm.nih.gov

Eugen Dhimolea. Canakinumab. „MAbs”. 2 (1), s. 3–13, 2010. DOI: 10.4161/mabs.2.1.10328. PMID: 20065636. PMCID: PMC2828573.
HJ Lachmann, Kone-Paut I, Kuemmerle-Deschner JB i wsp. Use of canakinumab in the cryopyrin-associated periodic syndrome. „New Engl J Med”. 360 (23), s. 2416–2425, 4 czerwca 2009. DOI: 10.1056/NEJMoa0810787. PMID: 19494217.

novartis.com

novartis.com

New biological therapy Ilaris approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease. Novartis, 200-06-18. [dostęp 2009-07-28]. [zarchiwizowane z tego adresu (2009-06-22)].

pharma.us.novartis.com

Ilaris – ulotka USA.

web.archive.org

New biological therapy Ilaris approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease. Novartis, 200-06-18. [dostęp 2009-07-28]. [zarchiwizowane z tego adresu (2009-06-22)].
Yuet Wan: Canakinumab (Ilaris) and rilonacept (Arcalyst) approved in EU for treatment of cryopyrin-associated periodic syndrome. National electronic Library for Medicines, 2009-10-29. [dostęp 2010-04-14]. [zarchiwizowane z tego adresu (2012-02-26)].